Novo Nordisk CEO open to NYSE upgrade

Novo Nordisk's chief executive said in a Financial Times interview reported September 23, 2026 that he sees advantages in moving the company's New York Stock Exchange listing from an American depositary receipt (ADR) structure to a direct listing of its ordinary shares^[1]. Mike Doustdar, who became CEO in 2025, put it this way: "I clearly do see some advantages with that."^[1] He was careful to add that no such change is under way^[2], but the comment reopened a question that has followed the Danish drugmaker for a decade: should the company behind semaglutide, sold in the US as Ozempic and Wegovy, trade in New York the same way it trades at home in Copenhagen?

What Doustdar actually said

Doustdar's comment came in response to a direct question about whether Novo would consider a direct NYSE listing to replace the ADR arrangement US investors currently use to buy the stock^[1]. He confirmed the idea has circulated inside the company for roughly a decade, but said there has been no "active dialogue or discussions" about it since he took over as chief executive^[1]. Asked about his general approach to strategic questions like this one, he offered a line that captures the whole story: "I'm a type who doesn't start with a 'no' typically; I start with 'maybe.'"^[1] He left the door open without committing to anything. Novo's own SEC filings still list its US shares as ADRs trading under the ticker NVO, with the company's primary listing on Nasdaq Copenhagen^[5].

Why a direct listing appeals to Novo at all

The arithmetic behind the idea is straightforward. More than half of Novo's revenue now comes from the United States, driven largely by diabetes and obesity medicines including Ozempic and Wegovy^[1]. The company's shareholder base has drifted away from Scandinavia over the past two decades as US funds have bought in^[1]. A direct listing would fold Novo into US stock indices that track primary shares rather than depositary receipts, which typically means deeper trading volume and a broader pool of institutional buyers.

The timing matters too. Novo became Europe's most valuable listed company in 2023, with a market value above $600 billion after the Wegovy launch, and its shares have since fallen more than 70% from that peak while rival Eli Lilly has gained ground^[1]. Two days before Doustdar's comments, Novo held a capital markets day where it laid out plans to diversify its drug portfolio and target more than five multi-blockbuster launches by 2030^[3]. A wider US investor base would not fix a competitive problem on its own, but it gives Novo more room to raise capital on favorable terms if it needs to fund manufacturing expansion or that pipeline.

What we don't know yet

No board decision, filing, or timeline exists. Doustdar's remarks were a response to a hypothetical, not an announcement, and a separate report on the same comments described the idea as "a future option rather than an active initiative"^[3]. We also don't know what a direct listing would mean for existing ADR holders, whether it would involve a change to Novo's dual-class share structure, or how Danish and European regulators would treat a shift in primary listing status. Readers should treat this as an early signal worth tracking, not a settled corporate plan. Nothing here is investment advice, and PeptideMethods does not cover Novo Nordisk stock as an investment recommendation of any kind.

Why this matters if you use semaglutide

A listing structure sounds like a finance story until you trace where the money goes. Novo's capacity to invest in manufacturing is not abstract for semaglutide users: the FDA only declared the Ozempic and Wegovy injection shortage resolved in February 2025, after two years of rationed supply, and it still warns that "patients and prescribers may still see intermittent and limited localized supply disruptions as the products move through the supply chain"^[4]. A deeper, more liquid US listing would not change a prescription or a price overnight. What it could do, if Novo ever follows through, is widen the company's access to the capital it uses to expand production lines and fund research behind its obesity and diabetes pipeline. The link between a stock-exchange technicality and whether the medicine stays in stock is real but indirect, and it stays hypothetical until Novo announces an actual plan rather than a CEO answering "what if" in an interview.

Medical disclaimer: This piece is for educational and journalistic purposes only and does not constitute medical or investment advice. Semaglutide is a prescription medicine where approved. Decisions about a prescribed medicine belong with a qualified clinician who knows the person's medical history. Nothing here is a recommendation to buy, sell, or hold Novo Nordisk stock. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.